Lenvatinib, a class of drugs known as tyrosine kinase inhibitors, delays the disease progression by an average of 15 months and also causes tumor shrinkage effectively. Know more: http://bit.ly/1nLGmYC #Oncology #CancerTreatment #MedicalBreakthrough #CancerNews